Oregon Health & Science University Patent applications |
Patent application number | Title | Published |
20160140382 | CELLULAR ACTIVITY QUANTIFICATION USING LABELED PROBES - Methods and systems for quantifying cellular activity using labeled probes, e.g., quantum dots, are disclosed. In one example approach, a method for quantifying cellular activity in a sample containing intact cells having labeled complexes comprises receiving images of the sample at a plurality of depths and detecting individual intact cells in the images of the sample at the plurality of depths. For each detected cell, discrete labels may be detected and localized in the cell at each depth, a total number of detected and localized labels may be calculated in the cell, and an activity level of the target molecule for the labeled probe in the cell determined. | 05-19-2016 |
20160120446 | HAND FUNCTION DIAGNOSTIC AND THERAPEUTIC SYSTEM - Systems, devices and methods for quantitatively assessing hand function strength and range of motion via various instrumentations are disclosed. In one example embodiment, a hand function diagnostic and therapeutic system includes distal and proximal finger flexion measurement apparatuses used to automate quantitative assessment of hand function based on a combination of strength, range of motion, and time performance metrics. | 05-05-2016 |
20160103127 | METHODS FOR DETECTING A MYCOBACTERIUM TUBERCULOSIS INFECTION - Methods for detecting an infection with Mtb in a subject are disclosed. The methods include detecting the presence of CD8 | 04-14-2016 |
20160102132 | MONOMERIC RECOMBINANT MHC MOLECULES USEFUL FOR MANIPULATION OF ANTIGEN-SPECIFIC T-CELLS - The present invention provides, in particular embodiments, for modified recombinant T cell receptor (TCR) ligands (RTLs) comprising a MHC class I or MHC class II component. The modified RTLs have redesigned surface features that preclude or reduce aggregation, wherein the modified molecules retain the ability to bind Ag-peptides, target antigen-specific T cells, inhibit T cell proliferation in an Ag-specific manner and have utility to treat, inter alia, autoimmune disease and other conditions mediated by antigen-specific T cells in vivo. | 04-14-2016 |
20160047811 | METHODS FOR ASSESSING THE RISK OF CARDIOVASCULAR DISEASE - The studies described herein demonstrate that γ′ fibrinogen and total fibrinogen are independent risk factors for cardiovascular disease. Further described herein is the unexpected finding that an elevated concentration of γ′ fibrinogen in combination with an elevated concentration of total fibrinogen is a significantly better predictor of cardiovascular disease risk than either marker alone. Thus, provided herein are methods of detecting a subject having cardiovascular disease, or at increased risk of developing a cardiovascular disease, by measuring both the concentration of γ′ fibrinogen and the concentration of total fibrinogen in a sample obtained from the subject. | 02-18-2016 |
20160040132 | THREE-DIMENSIONAL BIOPRINTED PANCREATIC TUMOR MODEL - Described are three-dimensional bioprinted pancreatic tumor tissue structures that are multilayer, multicellular three-dimensional structures generated with pancreatic cancer cells surrounded by cell types known to be found in the pancreatic tumor microenvironment. | 02-11-2016 |
20160031958 | METHODS AND COMPOSITIONS USEFUL IN MANIPULATING THE STABILITY OF RE1 SILENCING TRANSCRIPTION FACTOR - Disclosed are methods of screening for compounds that promote REST degradation by inhibiting the activity of the CDTSP1 phosphorylase including fluorescent and antibody based screens. Also disclosed are peptides that promote REST stabilization as well as antibodies that recognize REST phosphorylated at serine 861 and serine 864. | 02-04-2016 |
20160017334 | 5'-TRIPHOSPHATE OLIGORIBONUCLEOTIDES - Disclosed herein are synthetic oligoribonucleotides that form hairpin loop structures. The oligoribonucleotides can be used in the treatment of viral infection including prophylactic treatments. The oligoribonucleotides can also be used as adjuvants. | 01-21-2016 |
20160017297 | RECOMBINANT MANGANESE OXIDASE - Disclosed herein is a recombinant | 01-21-2016 |
20150374845 | COMPOUNDS THAT BIND DYSTROGLYCAN AND USES THEREOF - Disclosed herein are methods and compositions involved in identifying cells that lack apico-basal polarity as well as methods and compositions involved in selectively delivering payload molecules to cells that lack apico-basal polarity, and methods of selecting test compounds that restore apico-basal polarity. | 12-31-2015 |
20150343055 | COMPOSITIONS AND METHODS USING RECOMBINANT MHC MOLECULES FOR THE TREATMENT OF STROKE - Two-domain MHC polypeptides are useful for modulating activities of antigen-specific T-cells, including for modulating pathogenic potential and effects of antigen-specific T-cells. Exemplary MHC class II-based recombinant T-cell ligands (RTLs) of the invention include covalently linked β1 and α1 domains, and MHC class I-based molecules that comprise covalently linked α1 and α2 domains. These polypeptides may also include covalently linked antigenic determinants, toxic moieties, and/or detectable labels. The disclosed polypeptides can be used to target antigen-specific T-cells, and are useful, among other things, to detect and purify antigen-specific T-cells, to induce or activate T-cells, to modulate T-cell activity, including by regulatory switching of T-cell cytokine and adhesion molecule expression, to treat conditions mediated by antigen-specific T-cells, including treatment and/or prevention of central nervous system damage relating to stroke. | 12-03-2015 |
20150324978 | AQUEOUS CELL DIFFERENTIATION IN ANTERIOR UVEITIS USING OPTICAL COHERENCE TOMOGRAPHY - Methods and systems for determining a percentage composition of aqueous cells in an anterior chamber of an eye of a subject based on cell reflectance distributions calculated from OCT image data are disclosed. In one example approach, determining a percentage composition of detected aqueous cells may comprise calculating a percentage of the detected aqueous cells which are polymorphonuclear and calculating a percentage of detected aqueous cells which are mononuclear. | 11-12-2015 |
20150322163 | ANTI-FACTOR XI MONOCLONAL ANTIBODIES AND METHODS OF USE THEREOF - Compositions and methods for inhibiting thrombosis without compromising hemostasis are described. Compositions include anti-factor XI monoclonal antibodies (aXIMabs) capable of binding to an epitope on the heavy chain of human FXI, particularly the A3 domain of the heavy chain of human FXI. Compositions also include epitope-binding fragments, variants, and derivatives of the monoclonal antibodies, cell lines producing these antibody compositions, and isolated nucleic acid molecules encoding the amino acid sequences of the antibodies. The disclosure further includes pharmaceutical compositions comprising the disclosed anti-factor XI monoclonal antibodies, or epitope-binding fragments, variants, or derivatives thereof, in a pharmaceutically acceptable carrier. Methods of the disclosure include administering the compositions described above to a subject in need thereof for the purpose of inhibiting thrombosis, reducing a required dose of an antithrombotic agent in the treatment of thrombosis, treating metastatic cancer, or treating an acute inflammatory reaction. | 11-12-2015 |
20150310598 | CONTRAST REAGENT LEAKAGE CORRECTION IN DYNAMIC SUSCEPTIBILITY CONTRAST MAGNETIC RESONANCE IMAGING - Disclosed are methods and systems for calculating a contrast reagent (CR) extravasation rate constant and generating a contrast reagent leakage corrected relative cerebral blood volume (rCBV) image map of a brain region from dynamic susceptibility contrast (DSC) magnetic resonance imaging (MRI) time-course image data based on pharmacokinetic first principles. In one example approach, a computerized method may include performing a linearization transform of a DSC MRI time-course equation which accounts for an intravascular contribution and an extravasating component, and calculating CR leakage from a slope of a linear portion of the transformed data. | 10-29-2015 |
20150291680 | FORMULATIONS COMPRISING GLUCAGON - Glucagon formulations that resist fibril formation are disclosed. The formulations comprise curcumin derivatives such as ferulic acid and/or tetrahydrocurcumin and can further comprise human serum albumin, polysorbate-80, and L-methionine. | 10-15-2015 |
20150258339 | DEEP BRAIN ELECTRODE PLACEMENT AND STIMULATION BASED ON BROWN ADIPOSE TISSUE TEMPERATURE - Systems and methods for deep brain electrode placement and deep brain stimulation (DBS) for treatment of conditions such as obesity are disclosed. In one example approach, during placement of a deep brain stimulating electrode in a target region of the brain of a patient, a temperature of brown adipose tissue (BAT) may be monitored, e.g., via a supraclavicular temperature sensor implanted in the patient, and used to identify an optimal location of electrode stimulation which causes an increase in BAT temperature. Additionally, BAT temperature measurements may be used to provide regulated closed-loop control to increase efficiency of DBS while reducing energy consumption of the pulse generator. Further, core temperature measurements may be obtained from the electrode in the brain and used to adjust DBS. | 09-17-2015 |
20150219645 | METHODS FOR DETECTING A MYCOBACTERIUM TUBERCULOSIS INFECTION - Methods for detecting an infection with | 08-06-2015 |
20150202276 | METHODS FOR PRODUCING AN IMMUNE RESPONSE TO TUBERCULOSIS - Methods for producing an immune response to | 07-23-2015 |
20150181844 | FUMARYLACETOACETATE HYDROLASE (FAH)-DEFICIENT PIGS AND USES THEREOF - Described herein is the generation of Fah | 07-02-2015 |
20150157785 | DEVICES AND KITS USED IN HOLDING CYLINDRICAL OBJECTS - Devices for use in holding cylindrical objects are disclosed. The device includes a U-shaped portion that cradles the cylindrical object. The U-shaped portion comprises two arms. A straight portion is joined to one of the arms. The straight portion includes a hole traversing the length of the straight portion. The hole is configured to hold a fastener such as a screw or bolt. The fastener is in turn configured to engage a hole in an attachment mechanism. | 06-11-2015 |
20150157258 | METHOD AND APPARATUS FOR ASSESSMENT OF SLEEP APNEA - Methods and apparatuses for automatically identifying sleep apnea in a subject based on load cell signal data obtained from load cells coupled with one or more supports of a bed are disclosed. In one example approach, a method comprises continuously collecting load cell signal data from one or more load cells positioned below one or more supports of a bed, processing the signal data to obtain processed signal data, extracting features from the processed signal data, calculating a sleep apnea severity parameter based on the extracted features via a model, and identifying sleep apnea in the subject based on the sleep apnea severity parameter. | 06-11-2015 |
20150148708 | BIOFEEDBACK DURING ASSISTED MOVEMENT REHABILITATION THERAPY - Systems and methods for providing biofeedback during assisted movement rehabilitation therapy while a user is engaged with an assisted movement exercise device are disclosed. In one example approach, a method eliminates passively evoked involuntary torque from the biofeedback. In another example approach, a method eliminates unintentional torque produced by contraction of muscles antagonistic to the assisted movement. In another example approach, a method compensates for the length-tension property of muscle so that the biofeedback relates to the user's level of effort. | 05-28-2015 |
20150141804 | HIGH-RESOLUTION METABOLIC NEUROIMAGING - Provided herein are methods and apparatuses for determining a level of cellular metabolic activity for a region of interest in order to detect and map on-going gliovascular unit metabolic activity using high-resolution | 05-21-2015 |
20150132297 | SURVIVAL PREDICTOR FOR DIFFUSE LARGE B CELL LYMPHOMA - The invention provides methods and materials related to a gene expression-based survival predictor for DLBCL patients. | 05-14-2015 |
20150128299 | NORMALIZATION OF THE ENTEROHEPATIC CIRCULATION IN ANIMALS WITH A CHIMERIC HUMANIZED LIVER - Methods of normalizing bile acid production in a mouse engrafted with human hepatocytes by the administration of human FGF19 are disclosed. Also disclosed is a transgenic host animal, such as a mouse, that expresses human FGF19 that has normalized bile acid production when engrafted with human hepatocytes. | 05-07-2015 |
20150125955 | PD-1 MODULATION AND USES THEREOF FOR MODULATING HIV REPLICATION - Methods, uses, compositions and kits for modulating HIV replication based on PD-1 modulation are disclosed. Methods, uses, compositions and kits useful for the elimination of latent HIV reservoirs based on PD-1 inhibition are also disclosed. Methods and kits useful for identifying agents useful for modulating HIV replication are also disclosed. | 05-07-2015 |
20150099706 | TREATMENT OF ISCHEMIC STROKE WITH DRa1-MOG-35-55 - Methods and compositions used in treating ischemic stroke using a recombinant DRα-MOG-35-55 construct are disclosed. The disclosed methods involve administering a pharmaceutical composition comprising DRα-MOG-35-55 and a pharmaceutically acceptable carrier to a subject that has had or is at risk of developing ischemic stroke. | 04-09-2015 |
20150098956 | RECOMBINANT POLYPEPTIDES COMPRISING MHC CLASS II a1 DOMAINS - Recombinant polypeptides comprising a DRα1 domain, an antigenic peptide, and a linker sequence are disclosed. The linker sequence comprises a first glycine-serine spacer, a thrombin cleavage site and a second glycine-serine spacer. Further disclosed are pharmaceutical compositions comprising the recombinant polypeptides, methods of treating inflammatory disease using said pharmaceutical compositions, and expression constructs comprising nucleic acids that encode the recombinant polypeptides. | 04-09-2015 |
20150093395 | ANTI-FXI ANTIBODIES AND METHODS OF USE - Disclosed herein are monoclonal antibodies specific for factor XI (fXI) that prevent activation of fXI by factor XIIa (fXIIa). The monoclonal antibodies are universal fXI antibodies, capable of binding all mammalian species tested. The anti-fXI monoclonal antibodies prolong clotting time in mammalian plasmas. Moreover, administration of the fXI monoclonal antibodies disclosed herein results in inhibition of thrombosis without altering hemostasis in animal models of thrombosis. Thus, provided herein are monoclonal antibodies specific for fXI that block activation of fXI by fXIIa, compositions and immunoconjugates comprising such antibodies and their methods of use. | 04-02-2015 |
20150080914 | BIOABSORBABLE CLIPS AND APPLICATOR FOR TISSUE CLOSURE - Surgical clips and surgical applicators used in performing rapid tissue closure in either minimally invasive surgeries or traditional open procedures are provided. In one example approach, a surgical clip comprises opposing sides extending from a top portion and terminating at tips positioned below the top portion. The resting position of the clip is its closed position, and in the closed position, the tips are set at a first distance apart. Each side has a cut-out (or hole or aperture) opposite one another. Each cut-out is fully surrounded by the side and does not extend to the top or tips. Each cut-out is configured to engage an inwardly turned hook at the end of a clip array or clip applicator such that the sides bend outwardly away from each other when pressure is applied on the top portion of the clip, thereby placing the clip in an open position. | 03-19-2015 |
20150065378 | SYNTHETIC OLIGONUCLEOTIDES FOR DETECTION OF NUCLEIC ACID BINDING PROTEINS - Synthetic oligonucleotides that comprise a nucleic acid binding protein binding site, PCR primer sequences, and tag sequences that do not bind to nucleic acid binding proteins, with a total length of 85-130 nucleotides are disclosed herein. Also disclosed are libraries and kits comprising the synthetic oligonucleotides as well as methods of detecting nucleic acid binding proteins in a sample using the synthetic oligonucleotides. | 03-05-2015 |
20150037363 | RECOMBINANT T-CELL RECEPTOR LIGAND FOR THE TREATMENT OF COGNITIVE AND NEUROPSYCHIATRIC IMPAIRMENT INDUCED BY SUBSTANCE ADDICTION - Methods are provided for the treatment of subjects with cognitive or neuropsychiatric impairment induced by substance addiction and for increasing cognitive function in a subject with substance addiction. In some embodiments, the methods include administering to the subject a therapeutically effective amount of a major histocompatibility complex (MHC) molecule including covalently linked first, second, and third domains; wherein the first domain is an MHC class II β1 domain and the second domain is an MHC class II α1 domain; or wherein the first domain is an MHC class I α1 domain and the second domain is an MHC class I α2 domain; and wherein the third domain is covalently linked to the first domain and comprises an antigen of the central or peripheral nervous system. | 02-05-2015 |
20140378486 | PYRROLOQUINAZOLINE COMPOUNDS - Disclosed herein are acylated derivatives of 7H-pyrrolo[3,2-f]quinazoline-1,3-diamine and pharmaceutical compositions comprising said derivatives. | 12-25-2014 |
20140357704 | RTEF-1 VARIANTS AND USES THEREOF - Disclosed are variant RTEF-1 polypeptides having an RTEF-1 amino acid sequence with one or more internal deletions, wherein the polypeptides reduce VEGF promoter activity. Some of the RTEF-1 polypeptides include an amino acid sequence that is at least 80% identical to the contiguous amino acids of 1) amino acids 24 to 47 of SEQ ID NO:15 and 2) each of SEQ ID NOs:16 and 17, but does not comprise the contiguous amino acids of SEQ ID NOs:8, 9, 11, or 12. Also disclosed are nucleic acids encoding the variant RTEF-1 polypeptides of the present invention. Pharmaceutical compositions that include the polypeptides and nucleic acids of the present invention are also disclosed. Methods of inducing cell contact inhibition, regulating organ size, and reducing intracellular YAP activity are also set forth, as well as methods of treating hyperproliferative diseases such as cancer using the pharmaceutical compositions of the present invention. | 12-04-2014 |
20140336262 | PHARMACEUTICAL COMPOSITIONS COMPRISING NAPTHAMIDES - Disclosed herein are naphthamide and quinoline carboxamide compounds containing two bicyclic moieties, pharmaceutical compositions comprising those compounds and methods of using the compositions in the treatment of cancers mediated by cyclic-AMP (cAMP) response element binding protein (CREB). The disclosed compositions have utility in the treatment of lung, prostate and breast cancers in a human subject. | 11-13-2014 |
20140335619 | HUMAN PLURIPOTENT STEM CELLS PRODUCED BY SOMATIC CELL NUCLEAR TRANSFER - Human pluripotent embryonic stem cells produced by somatic cell nuclear transfer as well as methods of making and using said human pluripotent embryonic stem cells are disclosed. | 11-13-2014 |
20140335115 | SUPPRESSORS OF MATURE T CELLS - Disclosed herein is a viral polypeptide and homologs thereof that inhibit an immune response, particularly the response of memory and effector CD4 | 11-13-2014 |
20140322219 | ANTI-FACTOR XI MONOCLONAL ANTIBODIES AND METHODS OF USE THEREOF - The present invention relates to compositions and methods for inhibiting thrombosis without compromising hemostasis. Compositions include anti-factor XI monoclonal antibodies (aXIMabs) capable of binding to an epitope on the heavy chain of human FXI, particularly the A3 domain of the heavy chain of human FXI. Compositions also include epitope-binding fragments, variants, and derivatives of the monoclonal antibodies, cell lines producing these antibody compositions, and isolated nucleic acid molecules encoding the amino acid sequences of the antibodies. The invention further includes pharmaceutical compositions comprising the anti-factor XI monoclonal antibodies of the invention, or epitope-binding fragments, variants, or derivatives thereof, in a pharmaceutically acceptable carrier. Methods of the invention comprise administering the compositions described above to a subject in need thereof for the purpose of inhibiting thrombosis, reducing a required dose of an antithrombotic agent in the treatment of thrombosis, treating metastatic cancer, or treating an acute inflammatory reaction. | 10-30-2014 |
20140273152 | RECOMBINANT MANGANESE OXIDASE - Disclosed herein is a recombinant | 09-18-2014 |
20140248336 | SIRNA USEFUL IN THE TREATMENT OF FLAVIVIRUS INFECTION - Pharmaceutical compositions that comprise an siRNA molecule used in the treatment of diseases caused by flavivirus infection and methods of their use are disclosed. The pharmaceutical compositions treat diseases caused by yellow fever virus, West Nile virus, and dengue virus and include a single pharmaceutical composition active against all four dengue virus serotypes. | 09-04-2014 |
20140243332 | METHODS OF TREATING CANCERS CHARACTERIZED BY ABERRENT ROS1 ACTIVITY - Disclosed herein are methods of treating cancers characterized by aberrant ROS1 activity by administering an effective amount of foretinib (N1′-[3-fluoro-4-[[6-methoxy-7-(3-morpholinopropoxy)-4-quinolyl]oxy]phenyl]-N1-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide), including methods of identifying mutations in the kinase domain of ROS1 that indicate resistance to crizotinib, but sensitivity to foretinib. | 08-28-2014 |
20140212890 | METHODS, APPARATUSES, AND SYSTEMS FOR DETECTING AND QUANTIFYING PHOSPHOPROTEINS - Embodiments herein provide methods, apparatuses, and systems for detecting, monitoring, measuring, and/or characterizing the activity of phosphoproteins, such as tyrosine kinases (TKs) and downstream proteins in TK signal transduction pathways (e.g., TK pathway proteins). In various embodiments, the methods, apparatuses, and systems may use nanoparticles, such as quantum dots (QD), to detect and/or characterize the abnormally overactive TK signaling pathways that underlie tumorgenesis and tumor progression. In various embodiments, the QD-based methods, apparatuses, and systems may have a sufficiently high degree of sensitivity to enable the identification of new TK signaling pathway markers, for example for use in diagnosing, staging, monitoring, and/or prognosing cancers, or in evaluating the efficacy of cancer therapeutics. | 07-31-2014 |
20140163091 | METHODS USEFUL IN THE PREVENTION OF HYPOXIC INJURY - Methods useful in the treatment of cytotoxic insults such as excitotoxic injury, ischemic injury, and hypoxic injury are disclosed. The methods involve the treatment of the cytotoxic insult with a pharmaceutical composition comprising poly-ICLC. | 06-12-2014 |
20140141038 | CMV GLYCOPROTEINS AND RECOMBINANT VECTORS - Disclosed herein are recombinant CMV vectors which may comprise a heterologous antigen that can repeatedly infect an organism while inducing a CD8+ T cell response to immunodominant epitopes of the heterologous antigen. The CMV vector may comprise a deleterious mutation in the US 11 glycoprotein or a homolog thereof. | 05-22-2014 |
20140128423 | Acridone Compounds - A class of acridone compounds has been discovered that exhibits chemosensitizing and antiparasitic activity. Described herein are pharmaceutical compositions and methods for their use to treat parasitic infections, such as malaria and toxoplasmosis, and to sensitize resistant cells, such as multidrug resistant cells to other therapeutic agents. The pharmaceutical compositions and methods may also be used to treat and/or prevent psychotic diseases such as schizophrenia. | 05-08-2014 |
20140113297 | GENE EXPRESSION PREDICTORS OF CANCER PROGNOSIS - Disclosed herein are methods of predicting the prognosis of a subject with prostate cancer. The methods include determining the expression level of a gene product of one or more of ZWILCH, DEPDC1, TPX2, CDCA3, HMGB2, MYC, CDC20, and/or KIF11. Expression of the gene product above a threshold level of expression indicates a poor prognosis such as a likelihood of relapse. | 04-24-2014 |
20140099724 | FLUORESCENT DETECTION OF IN VITRO TRANSLATED PROTEIN ON A SOLID SURFACE - Disclosed herein are methods and kits useful in the detection of protein folding and in the identification of compounds that promote proper protein folding. In one example approach, fluorophores and a protein tag are incorporated into a nascent polypeptide within a ribosome-nascent-chain complex during cell free translation and the resulting labeled ribosome-nascent-chain complex is conjugated to a solid surface via the tag. Fluorescence imaging via FRET is then preformed to assess the folding state of the ribosome-nascent-chain complex under a variety of conditions. | 04-10-2014 |
20140088113 | METHODS AND KITS THAT IDENTIFY TUMORS RESPONSIVE TO SRC INHIBITORS - Disclosed herein are methods of predicting whether or not a subject will benefit from treatment with a Src inhibitor on the basis of the expression of one or more of Von Hippel Lindau (VHL), Src, PTP1B, pFAK, HIF-1α, and/or CA-IX in a tumor sample from the subject. | 03-27-2014 |
20140073917 | QUANTIFICATION OF LOCAL CIRCULATION WITH OCT ANGIOGRAPHY - Impaired intraocular blood flow within vascular beds in the human eye is associated with certain ocular diseases including, for example, glaucoma, diabetic retinopathy and age-related macular degeneration. A reliable method to quantify blood flow in the various intraocular vascular beds could provide insight into the vascular component of ocular disease pathophysiology. Using ultrahigh-speed optical coherence tomography (OCT), a new 3D angiography algorithm called split-spectrum amplitude-decorrelation angiography (SSADA) was developed for imaging microcirculation within different intraocular regions. A method to quantify SSADA results was developed and used to detect perfusion changes in early stage ocular disease. Associated embodiments relating to methods for quantitatively measuring blood flow at various intraocular vasculature sites, systems for practicing such methods, and use of such methods and systems for diagnosing certain ocular diseases are herein described. | 03-13-2014 |
20140058249 | METHOD AND APPARATUS USING MAGNETIC RESONANCE IMAGING FOR CANCER IDENTIFICATION - Embodiments provide a Magnetic Resonance Imaging (MRI) technique and optionally software—collectively referred to as the “shutter-speed” model—to analyze image data of cancer patients. Embodiments provide a minimally invasive, yet precisely accurate, approach to determining whether tumors are malignant or benign by distinguishing the characteristics of contrast reagent activity in benign and malignant tumors. Exemplary embodiments provide MRI measured biomarkers for tumor malignancy determination, effectively eliminating or limiting the false positives suffered by existing MRI techniques. | 02-27-2014 |
20140056936 | COMPOSITIONS AND METHODS USING RECOMBINANT MHC MOLECULES FOR THE TREATMENT OF STROKE - Two-domain MHC polypeptides are useful for modulating activities of antigen-specific T-cells, including for modulating pathogenic potential and effects of antigen-specific T-cells. Exemplary MHC class II-based recombinant T-cell ligands (RTLs) of the invention include covalently linked β1 and α1 domains, and MHC class I-based molecules that comprise covalently linked α1 and α2 domains. These polypeptides may also include covalently linked antigenic determinants, toxic moieties, and/or detectable labels. The disclosed polypeptides can be used to target antigen-specific T-cells, and are useful, among other things, to detect and purify antigen-specific T-cells, to induce or activate T-cells, to modulate T-cell activity, including by regulatory switching of T-cell cytokine and adhesion molecule expression, to treat conditions mediated by antigen-specific T-cells, including treatment and/or prevention of central nervous system damage relating to stroke. | 02-27-2014 |
20140045888 | COMPOUNDS HAVING ANTIPARASITIC OR ANTI-INFECTIOUS ACTIVITY - Compounds of formula I: | 02-13-2014 |
20140012061 | NON-INVASIVE LOCATION AND TRACKING OF TUMORS AND OTHER TISSUES FOR RADIATION THERAPY - Embodiments herein provide a non-invasive tracking system that accurately predicts the location of tumors, such as lung tumors, in real time, while allowing patients to breathe naturally. This is accomplished by using Electrical Impedance Tomography (EIT), in conjunction with spirometry, strain gauge and infrared sensors, and by using sophisticated patient-specific mathematical models that incorporate the dynamics of tumor motion. With the direction and speed of lung tumor movement successfully tracked, radiation may be effectively delivered to the lung tumor and not to the surrounding healthy tissue, thus increased radiation dosage may be directed to improving local tumor control without compromising functional parenchyma. | 01-09-2014 |
20130345152 | COMPOSITIONS COMPRISING RECOMBINANT COWPOX VIRUS PROTEIN CPXV014 - Disclosed herein are expression vectors that encode cowpox virus protein CPXV014 and homologs thereof that are useful in inhibiting CD3/CD28 mediated T cell stimulation. Further disclosed are polypeptide compositions comprising CPXV014 and homologs thereof as well as methods of inhibiting CD3/CD28 mediated T cell stimulation using the polypeptide compositions. | 12-26-2013 |
20130324503 | Method of identifying and treating a person having a predisposition to or afflicted with Parkinson disease - The present invention relates to methods of treatment for Parkinson Disease (PD) in a person by identifying gene variants which may indicate a more favorable response to specific medicaments, thereby allowing for personalized or individualized treatment. The present invention relates to a method of screening for a genetic predisposition to PD in a person. The present invention is also directed to a method of testing a person for the presence of particular gene variants, wherein the presence of a gene variant indicates a higher predisposition to PD, and the absence of a gene variant indicates a lower predisposition to PD, compared to a control sample. The present invention further relates to methods and kits for treating, or inhibiting the development of, PD in a person. The present invention is also directed to a method of identifying the heritage of an individual based on the genetic profile of the individual. | 12-05-2013 |
20130316338 | CCR6 As A Biomarker of Alzheimer's Disease - Disclosed are methods used to diagnose Alzheimer's disease (AD) in a subject. The methods involve determining the amount of chemokine receptor 6 (CCR6) expressed in a biological sample. Expression of CCR6 in the sample that exceeds a threshold level of expression signifies that the subject has AD, even if the subject has not yet developed symptoms of AD. The methods may also be used to monitor the effectiveness of an AD treatment. Kits that facilitate the use of the methods are also disclosed. | 11-28-2013 |
20130309229 | RECOMBINANT T CELL LIGANDS AND ANTIBODIES THAT BIND B CELLS FOR THE TREATMENT OF AUTOIMMUNE DISEASES - Methods are disclosed for treating or inhibiting an autoimmune disease in a subject. In some embodiments, the disclosed methods include administering to the subject a therapeutically effective amount of one or more Major Histocompatibility Complex (MHC) molecules including covalently linked first, second and third domains; wherein the first domain is an MHC class II β1 domain and the second domain is an MHC class II α1 domain, wherein the amino terminus of the α1 domain is covalently linked to the carboxy terminus of the β1 domain; or wherein the first domain is an MHC class I α1 domain and the second domain is an MHC class I α2 domain, wherein the amino terminus of the α2 domain is covalently linked to the carboxy terminus of the α1 domain; and wherein the third domain is covalently linked to the first domain and comprises an antigen associated with the autoimmune disorder. The method also includes administering a therapeutically effective amount of one or more antibodies that bind to B cells, for example an antibody that specifically binds CD20. In specific non-limiting examples, the autoimmune disease is multiple sclerosis or rheumatoid arthritis. | 11-21-2013 |
20130284599 | REVERSIBLE CURRENT GEL ELECTROPHORESIS DEVICE FOR SEPARATING BIOLOGICAL MACROMOLECULES - Cassette bodies for use with electrophoresis apparatus can be formed of a single piece of molded or machined plastic. Such cassette bodies can include a plurality of channels that pass through the cassette body, from a proximal end to a distal end. Such channels can be defined by upper and lower chambers. The upper chambers can be in fluid communication with a first buffer pool through a semi-permeable membrane, and the lower chambers can be in fluid communication with a second buffer pool. An electric current can be passed through the first and second buffer pools, and then reversed, to perform an electrophoresis operation that can separate a biomolecule of interest from free probes, and provide for convenient collection of said biomolecule of interest. | 10-31-2013 |
20130273542 | DETECTION OF GLEEVEC RESISTANCE - The present invention relates to isolated polypeptides which comprise an amino acid sequence consisting of a mutated functional Abl kinase domain, said mutated functional kinase domain being resistant to inhibition of its tyrosine kinase activity by N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-4-(4-methyl-piperazin-1-ylmethyl)-benzamide or a salt thereof, to the use of such polypeptides to screen for compounds which inhibit the tyrosine kinase activity of such polypeptides, to nucleic acid molecules encoding such polypeptides, to recombinant vectors and host cells comprising such nucleic acid molecules and to the use of such nucleic acid molecules in the production of such polypeptides for use in screening for compounds which inhibit the tyrosine kinase activity of such polypeptides. | 10-17-2013 |
20130267828 | METHOD AND APPARATUS FOR NONINVASIVE QUANTITATIVE DETECTION OF FIBROSIS IN THE HEART - Embodiments provide a noninvasive quantitative method for detecting extent and/or types of fibrosis in the heart. In embodiments, information pertaining to the extent and/or types of fibrosis may aid in the diagnosis of specific cardiac diseases and heart failure and/or may assist in determining suitable treatment options. Embodiments provide methods and apparatuses for determining the extent of fibrosis in viable and nonviable myocardium, which may then be correlated to heart disease and failure. Thus, in an embodiment, a method of screening individuals for the purpose of heart disease or heart failure prevention may be provided using the detection methodology described herein. | 10-10-2013 |
20130210748 | METHOD AND PEPTIDE FOR REGULATING CELLULAR ACTIVITY - Method and peptide for regulating cellular activity includes a panel of synthesized peptides that have biological effects on inhibiting or enhancing cellular activity. Selected peptides can be used as therapy to reduce and/or inhibit, or initiate and/or enhance, an inflammatory response in a subject. | 08-15-2013 |
20130191931 | FUMARYLACETOACETATE HYDROLASE (FAH)-DEFICIENT PIGS AND USES THEREOF - Described herein is the generation of Fah | 07-25-2013 |
20130190221 | MONOMERIC RECOMBINANT MHC MOLECULES USEFUL FOR MANIPULATION OF ANTIGEN-SPECIFIC T-CELLS - The present invention provides, in particular embodiments, for modified recombinant T cell receptor (TCR) ligands (RTLs) comprising a MHC class I or MHC class II component. The modified RTLs have redesigned surface features that preclude or reduce aggregation, wherein the modified molecules retain the ability to bind Ag-peptides, target antigen-specific T cells, inhibit T cell proliferation in an Ag-specific manner and have utility to treat, inter alia, autoimmune disease and other conditions mediated by antigen-specific T cells in vivo. | 07-25-2013 |
20130171179 | RECOMBINANT T-CELL RECEPTOR LIGANDS WITH COVALENTLY BOUND PEPTIDES - Disclosed herein are stable complexes including an MHC class I or MHC class II recombinant T cell receptor ligand RTL polypeptide covalently linked to an antigenic determinant by a disulfide bond. Also disclosed are methods of making such compositions and methods of use, for example to treat or inhibit a disorder, for example, an autoimmune disorder. | 07-04-2013 |
20130171144 | ANTI-FACTOR XI MONOCLONAL ANTIBODIES AND METHODS OF USE THEREOF - The present invention relates to compositions and methods for inhibiting thrombosis without compromising hemostasis. Compositions include anti-factor XI monoclonal antibodies (aXIMabs) capable of binding to an epitope on the heavy chain of human FXI, particularly the A3 domain of the heavy chain of human FXI. Compositions also include epitope-binding fragments, variants, and derivatives of the monoclonal antibodies, cell lines producing these antibody compositions, and isolated nucleic acid molecules encoding the amino acid sequences of the antibodies. The invention further includes pharmaceutical compositions comprising the anti-factor XI monoclonal antibodies of the invention, or epitope-binding fragments, variants, or derivatives thereof, in a pharmaceutically acceptable carrier. Methods of the invention comprise administering the compositions described above to a subject in need thereof for the purpose of inhibiting thrombosis, reducing a required dose of an antithrombotic agent in the treatment of thrombosis, treating metastatic cancer, or treating an acute inflammatory reaction. | 07-04-2013 |
20130136768 | Recombinant HCMV and RHCMV vectors and uses thereof - Described herein are recombinant rhesus cytomegalovirus (RhCMV) and human cytomegalovirus (HCMV) vectors encoding heterologous antigens, such as pathogen-specific antigens or tumor antigens. The recombinant vectors elicit and maintain high level cellular and humoral immune responses specific for the heterologous antigen. The recombinant RhCMV and HCMV vectors may be used, for example, for the treatment or prevention of infectious disease or cancer. In some examples, the recombinant RhCMV or HCMV vectors may include deletions in genes encoding immunomodulatory proteins. In some examples, the recombinant RhCMV or HCMV vectors may be deficient or impaired in their ability to replicate within a cell, disseminate within the host or spread among hosts by including a deletion in one or more genes essential or augmenting for CMV replication, dissemination or spread. | 05-30-2013 |
20130131542 | METHOD AND APPARATUS FOR TINNITUS EVALUATION - Methods, articles of manufacture, and systems for evaluating tinnitus are disclosed herein. According to various embodiments, a tinnitus evaluation system may include a tinnitus evaluation module configured to perform one or more tinnitus evaluation tests. A tinnitus evaluation test may comprise generating a first single-frequency sound based at least in part on a sound of a patient's tinnitus, and generating a narrow-band sound centered at the frequency of the first single-frequency sound. Tests include a hearing threshold test, a loudness match test, a pitch match test, a bandwidth match test, a minimum masking level test, and a residual inhibition test. | 05-23-2013 |
20130131139 | ROR1 AS A GENE TARGET IN ACUTE LYMPHOBLASTIC LEUKEMIA - Disclosed are methods of selecting a subject suspected of having or having leukemia, such as lymphoblast leukemia (B-ALL), for treatment with an agent that inhibits ROR1-regulated signaling activity. In some examples, cells obtained from the subject are screened for over expression of ROR1. In other examples, the cells are contacted with an agent that inhibits ROR1 signaling activity and a ROR1-regulated signaling activity is detected. An alteration in the ROR1-regulated signaling activity as compared to a control identifies the subject as one that would benefit from treatment with an agent that inhibits ROR1 signaling activity. Also disclosed are methods for identifying an agent for treating a subject with a ROR1-dependent leukemia or with a predisposition for developing a ROR1-dependent leukemia, and methods for treating or inhibiting a ROR1-dependent leukemia, such as B-ALL in a subject. | 05-23-2013 |
20130129745 | ANTI-FXI ANTIBODIES AND METHODS OF USE - Disclosed herein are monoclonal antibodies specific for factor XI (fXI) that prevent activation of fXI by factor XIIa (fXIIa). The monoclonal antibodies are universal fXI antibodies, capable of binding all mammalian species tested. The anti-fXI monoclonal antibodies prolong clotting time in mammalian plasmas. Moreover, administration of the fXI monoclonal antibodies disclosed herein results in inhibition of thrombosis without altering hemostasis in animal models of thrombosis. Thus, provided herein are monoclonal antibodies specific for fXI that block activation of fXI by fXIIa, compositions and immunoconjugates comprising such antibodies and their methods of use. | 05-23-2013 |
20130101523 | METHODS FOR DETECTING A MYCOBACTERIUM TUBERCULOSIS INFECTION - Methods for detecting an infection with | 04-25-2013 |
20130079607 | FIBEROPTIC PROBE FOR MEASURING TISSUE OXYGENATION AND METHOD FOR USING SAME - Embodiments herein relate to the field of medical monitoring, and, more specifically, to a fiberoptic probe for monitoring tissue oxygenation and a method for using such a probe. A non-invasive method of measuring tissue oxygenation includes, in some embodiments, illuminating a tissue surface with a first fiberoptic fiber, receiving light from the tissue surface with a second fiberoptic fiber, measuring the absorption spectra of oxy- and deoxy-hemoglobin in the light, and calculating a tissue oxygenation value based on the absorption spectra. | 03-28-2013 |
20130065840 | METHOD AND PEPTIDE FOR REGULATING CELLULAR ACTIVITY - Method and peptide for regulating cellular activity includes a panel of synthesized peptides that have biological effects on inhibiting or enhancing cellular activity. Selected peptides can be used as therapy to reduce and/or inhibit, or initiate and/or enhance, an inflammatory response in a subject. | 03-14-2013 |
20130064807 | USE OF THROMBIN MUTANTS TO INHIBIT THE ANTICOAGULATION EFFECT OF THROMBIN INHIBITORS - The present disclosure provides methods for inhibiting the anticoagulation effect of a thrombin inhibitor in a patient in need thereof comprising administration of a therapeutically effective amount of a variant prothrombin or thrombin that is capable of binding the thrombin inhibitor and that has reduced procoagulant activity. Variant prothrombins or thrombins of use in the methods of the present disclosure include thrombin mutants W215A, W215A/E217A, or variants thereof in which the amino acids at positions 215 and/or 217 are alanine. Methods are also provided in which the thrombin mutants are administered with an additional active agent. In one embodiment, the methods are useful in the treatment of patients in which a direct thrombin inhibitor has been administered. The present disclosure further provides a method for quantifying the concentration of an anticoagulant in the plasma or whole blood of a patient using a variant prothrombin or thrombin titration assay. | 03-14-2013 |
20120330413 | Biomedical Valve Devices, Support Frames for Use in Such Devices, and Related Methods - Biomedical valve devices, support frames for use in such devices, methods of making such devices, and methods of treating animals, including humans, for valve-related conditions are described. The biomedical valve devices can includes a native tissue valve attached to a support frame or a tissue attached to a support frame in a manner to form a valve. The tissue valve or tissue can be autogenous to the animal being treated. | 12-27-2012 |
20120307014 | METHOD AND APPARATUS FOR ULTRAHIGH SENSITIVE OPTICAL MICROANGIOGRAPHY - Embodiments herein provide an ultrahigh sensitive optical microangiography (OMAG) system that provides high sensitivity to slow flow information, such as that found in blood flow in capillaries, while also providing a relatively low data acquisition time. The system performs a plurality of fast scans (i.e., B-scans) on a fast scan axis, where each fast scan includes a plurality of A-scans. At the same time, the system performs a slow scan (i.e., C-scan), on a slow scan axis, where the slow scan includes the plurality of fast scans. A detector receives the spectral interference signal from the sample to produce a three dimensional (3D) data set. An imaging algorithm is then applied to the 3D data set in the slow scan axis to produce at least one image of the sample. In some embodiments, the imaging algorithm may separate flow information from structural information of the sample. | 12-06-2012 |
20120219205 | NONINVASIVE ASSESSMENT OF KERATINOCYTES - Embodiments herein provide methods for noninvasive assessment of keratinocytes. Digital imaging and processing of gray-levels are used to identify cells. More specifically, embodiments provide an automated algorithm that may be used to identify keratinocytes, and/or to specify the coordinates/locations of keratinocytes, through noninvasive confocal imaging. | 08-30-2012 |
20120209152 | METHOD OF REHABILITATING INDIVIDUALS EXPERIENCING LOSS OF SKELETAL JOINT MOTOR CONTROL - A method and device assist in the rehabilitation of patients who have suffered loss of motor control of an appendicular joint due to neurological damage. The method includes attempted contraction by a patient of a muscle that serves to move an affected joint coupled with the production of a perception by the patient that the joint is being moved more than it really is. The method results in dramatic non-transient improvements in motor control of the joint. The device provides an apparatus for performance of the method. | 08-16-2012 |
20120201903 | CYTOPROTECTIVE OR THERAPEUTIC PLANT COMPOSITION - Embodiments herein provide plant compositions, and, more specifically, a plant composition including | 08-09-2012 |
20120178667 | METHODS FOR TREATING SEPTIC SHOCK - Methods for the treatment of septic shock are disclosed herein. The methods include the use of a therapeutically effective amount of inhibitory peptides that inhibit TLR activity. The peptides can be used with other agents for the treatment of septic shock. In one embodiment, a therapeutically effective amount of a peptide is administered to a subject with septic shock, such as septic shock induced by an infection with gram negative bacteria. | 07-12-2012 |
20120174325 | MODULAR BICYCLE GUTTER - Embodiments herein provide a modular gutter for use by bicycles and other conveyances. When utilized, a conveyance may be guided along the gutter either by an individual on the conveyance or adjacent to it, whether up or down the gutter. The gutter may be manufactured in various lengths and arrangements, and additionally, the components of the gutter are designed to permit multiple subunits to be coupled to form longer gutters. Alternatively, the gutters may be cut to a desired length should the manufactured length be too long. Thus, the gutter may be sized for any of a variety of staircases. The gutter may be removably installed on existing staircases without the need to redesign or reconstruct the staircase. | 07-12-2012 |
20120170828 | AUTOMATED DETECTION OF MELANOMA - Embodiments herein exploit the optical sectioning capability of reflectance confocal microscopy to non-invasively survey the dermal-epidermal junction (DEJ), noting the irregularities associated with malignancy. Methods are provided to aid a clinician in diagnosing melanoma through pattern recognition to extract pertinent diagnostic information from large 3D confocal images. Identifying the combination of pagetoid melanocytes and DEJ breakdown increases the accuracy of detection. A method may be used to process a 3D confocal volume of images taken by a clinician of a suspicious lesion and deduce the depth location z of the first reflective surface (FRS) at each x-y position. This FRS is where the most superficial melanin resides. In this manner, the stratum corneum and epidermis are digitally stripped and no longer distract the clinician from the more diagnostically relevant pigmented cell network. The FRS is putatively either the DEJ for benign nevi or the depth of a pagetoid melanocyte at x,y above the DEJ. Thus by creating a 3D surface plot of the FRS for each lateral x,y point, the presence of pagetoid cells is identified by a discreet jump in the FRS above the level of the DEJ. The DEJ map may also be used to determine if breakdown of the DEJ is occurring. | 07-05-2012 |
20120116187 | METHOD AND APPARATUS FOR ASSESSMENT OF SLEEP DISORDERS - Embodiments provide systems, methods and apparatuses for monitoring the sleep of a subject in a home environment. In embodiments, load cells placed under bed supports may be coupled to a computing device that may process the load cell data to detect disordered breathing. In some embodiments, a computing device may apply a pattern recognition algorithm to load cell data to distinguish between normal movements and movements associated with a sleep disorder. In an embodiment, apparatuses and methods for monitoring sleep may perform functions associated with detection of sleep disturbances and/or identify a sleep disorder. | 05-10-2012 |
20120115904 | COMPOUNDS HAVING ANTIPARASITIC OR ANTI-INFECTIOUS ACTIVITY - Compounds of formula I: | 05-10-2012 |
20120114936 | THIN LAYER SUBSTRATE COATING AND METHOD OF FORMING SAME - Embodiments of the present invention relate to coating deposition and coatings for dental and orthopedic devices that provide prevention or reduction of ion leakage and, in some situations, improved aesthetic appearances. | 05-10-2012 |
20120088255 | HER-2 BINDING ANTAGONISTS - There is disclosed a pharmaceutical composition for treating solid tumors that overexpress HER-2, comprising an agent selected from the group consisting of (a) an isolated polypeptide having from about 50 to 79 amino acids taken from the sequence of SEQ ID NO:1, wherein the polypeptide binds to the extracellular domain ECD of HER-2 at an affinity of at least 10 | 04-12-2012 |
20120063665 | METHOD AND APPARATUS FOR QUANTITATIVE IMAGING OF BLOOD PERFUSION IN LIVING TISSUE - Embodiments provide methods and systems for imaging, and, more specifically, to a method and apparatus for quantitative imaging of blood perfusion in living tissue. Some embodiments are directed to methods of obtaining quantitative imaging of blood perfusion in living tissues using Doppler optical micro-angiography (DOMAG). | 03-15-2012 |
20120045755 | HER-2 BINDING ANTAGONISTS - There is disclosed a pharmaceutical composition for treating solid tumors that overexpress HER-2, comprising an agent selected from the group consisting of (a) an isolated polypeptide having from about 50 to 79 amino acids taken from the sequence of SEQ ID NO. 1 or SEQ ID NO:12, wherein the polypeptide binds to the extracellular domain ECD of HER-2 at an affinity of at least 10 | 02-23-2012 |
20120014881 | METHODS FOR DETECTING A MYCOBACTERIUM TUBERCULOSIS INFECTION - Methods for detecting an infection with | 01-19-2012 |
20120010237 | COMPOUNDS HAVING ANTIPARASITIC OR ANTI-INFECTIOUS ACTIVITY - A method for inhibiting a parasitic or infectious disease in a subject, wherein the parasitic or infectious disease is selected from one caused by | 01-12-2012 |
20110313262 | METHOD AND APPARATUS FOR PREVENTION OF APNEA - Embodiments provide a continuous monitor of a patient's oxygenation and/or respiration coupled to a device configured to stimulate the patient's respiratory drive and/or summon medical assistance. In embodiments, there are provided systems, devices, and methods to assist in preventing patients from overdosing themselves with narcotics post-surgery. In embodiments, an apnea prevention device (APD) may utilize a commercially available pulse oximeter and/or a respiratory monitor to continuously monitor a patient's level of oxygenation/respiration. Should a patient develop respiratory depression or apnea and begin to desaturate, an APD may, using a proprietary method, trigger a sequence of staged responses to reverse worsening hypoxia. | 12-22-2011 |
20110262479 | RECOMBINANT MHC MOLECULES USEFUL FOR MANIPULATION OF ANTIGEN-SPECIFIC T-CELLS - Two-domain MHC polypeptides useful for manipulation of antigen-specific T-cells are disclosed. These polypeptides include MHC class II-based molecules that comprise covalently linked β1 and α1 domains, and MHC class I-based molecules that comprise covalently linked α1 and α2 domains. These polypeptides may also include covalently linked antigenic determinants, toxic moieties, and/or detectable labels. The disclosed polypeptides can be used to target antigen-specific T-cells, and are useful, among other things, to detect and purify antigen-specific T-cells, to induce or activate T-cells, and to treat conditions mediated by antigen-specific T-cells. | 10-27-2011 |
20110228907 | HEAD AND NECK RADIATION LOCALIZATION USING ORAL APPLIANCE - In various embodiments, methods, apparatuses, and systems for accurate patient positioning and motion tracking before and/or during head and neck radiation therapy, such as intensity modulated radiation therapy, are provided. In exemplary embodiments, a computing system may be endowed with one or more components of the disclosed apparatuses and/or systems and may be employed to perform one or more methods as disclosed herein. Exemplary embodiments provide head and neck radiation localization using, in part, an oral appliance. | 09-22-2011 |
20110201917 | METHOD AND APPARATUS USING MAGNETIC RESONANCE IMAGING FOR CANCER IDENTIFICATION - Embodiments provide a Magnetic Resonance Imaging (MRI) technique and optionally software—collectively referred to as the “shutter-speed” model—to analyze image data of cancer patients. Embodiments provide a minimally invasive, yet precisely accurate, approach to determining whether tumors are malignant or benign by distinguishing the characteristics of contrast reagent activity in benign and malignant tumors. Exemplary embodiments provide MRI measured biomarkers for tumor malignancy determination, effectively eliminating or limiting the false positives suffered by existing MRI techniques. | 08-18-2011 |
20110195064 | SURVIVAL PREDICTOR FOR DIFFUSE LARGE B CELL LYMPHOMA - The invention provides methods and materials related to a gene expression-based survival predictor for diffuse large B cell lymphoma (DLBCL) patients. | 08-11-2011 |
20110194075 | METHOD AND APPARATUS FOR VISUAL FIELD MONITORING - Embodiments provide methods and systems for the modeling and analysis of visual fields. Methods for global and regional measurement of visual sensitivity and quantification of field loss are provided in accordance with various embodiments. Further embodiments provide systems and methods for the diagnosis of diseases affecting the visual field. In addition, embodiments provide methods and systems for measuring and quantifying the volume of the Hill of Vision for an individual subject. | 08-11-2011 |
20110116694 | RAPID CONFOCAL MICROSCOPY TO SUPPORT SURGICAL PROCEDURES - One embodiment of techniques for confocal microscopy includes illuminating a spot on a surface of a biological sample. A first emission intensity from the spot is detected in a first range of optical properties; and a second emission intensity in a second range. A pixel that corresponds to the spot is colored using a linear combination of the first and second emission intensities. Sometimes, the pixel is colored to approximate a color produced by histology. In some embodiments, a surface of a sample is contacted with a solution of acridine orange. Then, a spot is illuminated with a laser beam of wavelength about 488 nanometers (nm). Fluorescence emission intensity is detected above about 500 nm. Sometimes, a certain illumination correction is applied. In some embodiments, a sample holder that compresses a sample is removable from a stage that is fixed with respect to a focal plane of the microscope. | 05-19-2011 |
20110092860 | SYSTEM FOR CLINICAL ASSESSMENT OF MOVEMENT DISORDERS - According to one embodiment of the present invention, the system for clinical assessment of movement disorders (iTUG) is comprised of a) a protocol to assess gait, balance, and mobility; b) a plurality of wearable sensors including accelerometers, gyroscopes, magnetometers, optical sensors, and goniometers to record kinematics data obtained from a patient during said protocol; c) means for wirelessly transmitting said kinematics data to a storage and data processing server; and d) a plurality of statistical and biomedical signal processing methods to analyze said kinematic data and derive a plurality of metrics (outcomes) to objectively quantify movement disorders. A specially important outcome for the assessment of movement disorders is described, namely, the quantification of the onset and offset parameters during turning. A method for quantification of said onset and offset turning parameters involves 1) collecting data to measure the angle of the trunk during turning, 2) modeling said angle using a mathematical model, and 3) using numerical optimization and estimation methods for fitting the model in the data to determine said onset and offset turning parameters. | 04-21-2011 |
20110081730 | ACTIVATING MUTATIONS OF PLATELET DERIVED GROWTH FACTOR RECEPTOR ALPHA (PDGFRA) AS DIAGNOSTIC MARKERS AND THERAPEUTIC TARGET - This disclosure provides tyrosine kinase protein and nucleic acid variants, particularly PDGFRA variants, which are activating forms of these molecules and are linked to neoplasms and/or the development or progression of cancer. The disclosure further provides methods of diagnosis and prognosis, and development of new therapeutic agents using these molecules and fragments thereof, and kits for employing these methods and compositions. | 04-07-2011 |
20110053830 | METHODS FOR TREATING SEPTIC SHOCK - Methods for the treatment of septic shock are disclosed herein. The methods include the use of a therapeutically effective amount of inhibitory peptides that inhibit TLR activity. The peptides can be used with other agents for the treatment of septic shock. In one embodiment, a therapeutically effective amount of a peptide is administered to a subject with septic shock, such as septic shock induced by an infection with gram negative bacteria. | 03-03-2011 |
20110046482 | METHODS FOR REDUCING TOXICITIES ASSOCIATED WITH MEDICAL PROCEDURES EMPLOYING RADIOGRAPHIC CONTRAST AGENTS - Improved methods of administration of thiol-based agents, such as NAC (N-acetylcysteine) and STS (sodium thiosulfate), are provided that protect against renal and other organ injury caused by diagnostic or therapeutic intra-arterial procedures which employ radiographic contrast agents. | 02-24-2011 |
20110014224 | METHODS FOR PRODUCING AN IMMUNE RESPONSE TO TUBERCULOSIS - Methods for producing an immune response to | 01-20-2011 |
20110004099 | METHOD AND APPARATUS USING ULTRASOUND FOR ASSESSING INTRACARDIAC PRESSURE - Embodiments relate to the field of hemodynamics, and, more specifically, to non-invasive methods of intracardiac pressure assessment. Some embodiments include acquiring ultrasound image data of a right internal jugular (IJ) vein in a subject, processing the ultrasound image data to determine vascular characteristic data for the IJ vein, and determining the right-sided intracardiac pressure from the vascular characteristic data. Also disclosed are systems and apparatus for carrying out the methods. | 01-06-2011 |
20100316653 | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF ORTHOPOXVIRUSES - In particular aspects, the invention provides a novel approach for the systematic analysis and identification of biologically relevant epitopes (SABRE). SABRE-identified polypeptides have diagnostic (e.g., polypeptide arrays, etc.) and/or therapeutic (e.g., vaccines, etc.) utility, and utility for developing monoclonal antibodies having diagnostic and/or therapeutic utility (e.g. for detecting and/or preventing orthopoxvirus infection). Preferred aspects provide high-throughput assays for detecting specific orthopoxvirus infection, for detecting orthopoxvirus-specific immune response, or for dual (parallel) determination of both orthopoxvirus immune response and orthopoxvirus infection. Additional preferred and surprising aspects provide novel high-throughput methods for detecting ‘protective immunity’ against orthopoxviruses (e.g., for detecting protective immunity against smallpox virus and monkeypox virus), based on anti-vaccinia virus serum antibody levels. The inventive diagnostic assays are rapid, high-throughput and suitable for ‘point-of-care’ implementations. | 12-16-2010 |
20100268230 | METHOD AND APPARATUS FOR DENS FRACTURE FIXATION - Embodiments of the present invention provide methods, apparatuses, and systems for fixing dens fractures. The mode of failure for screw fixation of C2 dens fractures is often via cut-out at the anterior body. In an embodiment, securing a plate, such as a locking plate, to the anterior surface of the vertebra attached directly to an interfragmentary screw may reduce potential for anterior screw cut-out and improve construct strength. Plate supplementation of anterior screw fixation of Type II dens fractures thus improves construct strength and changes the failure mechanism from anterior screw cut-out to posterior displacement of the screw, thus improving clinical outcomes for these fractures. | 10-21-2010 |
20100268188 | DRUG DELIVERY CUFF - Embodiments provide a drug delivery cuff including a drug reservoir. In an embodiment, an integrated drug pump may be provided. A drug delivery cuff in accordance with an embodiment may be placed around any suitable vascular graft (e.g., ePTFE) or directly around any natural tissue conduit (e.g., perivascularly), at any position along the graft/conduit or overlapping a graft and conduit, either at the time of graft surgical placement or separate therefrom. | 10-21-2010 |
20100267027 | HER-2 BINDING ANTAGONISTS - There is disclosed a a pharmaceutical composition for treating solid tumors that overexpress HER-2, comprising an agent selected from the group consisting of (a) an isolated polypeptide having from about 50 to 79 amino acids taken from the sequence of SEQ ID NO:1, wherein the polypeptide binds to the extracellular domain ECD of HER-2 with an affinity binding constant of at least 10 | 10-21-2010 |
20100233211 | ATTENUATED FRANCISELLA AND METHODS OF USE - is the bacterial pathogen that causes tularemia in humans and a number of animals. To date, no approved vaccine exists for this widespread and life-threatening disease. The present disclosure provides attenuated | 09-16-2010 |
20100222712 | BIAS-PROBE ROTATION TEST OF VESTIBULAR FUNCTION - Apparatus and methods for rotation test stimulus and analysis methods overcome many of the limitations of traditional clinical tests of peripheral vestibular function. An embodiment includes a rotational stimuli applied to the rotational motion for testing that includes two separate components, a bias component and a probe component. The bias component for rotational motion is designed to temporarily turn off vestibular responses in one ear while the responsiveness in the opposite ear is simultaneously evaluated using the probe component of the stimulus. Responses from application of these stimuli are analyzed by isolating and separating the bias response from the probe response. The bias and probe component responses are parameterized by applying curve fits of mathematical functions to the isolated bias and probe component responses. These parameters characterize the patient's vestibular function. | 09-02-2010 |
20100129923 | TANDEM MASS SPECTROMETRY FOR DETECTING AND/OR SCREENING FOR CONDITIONS ASSOCIATED WITH ALTERED STEROLS - Embodiments of the present invention provide for detecting and/or screening for conditions associated with altered sterols by dehvatization of sterols to provide suitable sensitivity and selectivity of detection using tandem mass spectrometry with electrospray ionization. Such testing may be performed to detect and/or screen for conditions such as Smith-Lemli-Opitz syndrome, familial hypercholesterolemia, and cerebrotendinous xanthomatosis, or certain bile acid disorders. | 05-27-2010 |
20100129292 | METHOD AND APPARATUS FOR NONINVASIVE QUANTITATIVE DETECTION OF FIBROSIS IN THE HEART - Embodiments provide a noninvasive quantitative method for detecting extent and/or types of fibrosis in the heart. In embodiments, information pertaining to the extent and/or types of fibrosis may aid in the diagnosis of specific cardiac diseases and heart failure and/or may assist in determining suitable treatment options. Embodiments provide methods and apparatuses for determining the extent of fibrosis in viable and nonviable myocardium, which may then be correlated to heart disease and failure. Thus, in an embodiment, a method of screening individuals for the purpose of heart disease or heart failure prevention may be provided using the detection methodology described herein. | 05-27-2010 |
20100125950 | ACCESSORY PANEL FOR DIAGNOSTIC PLATFORM, PATIENT BED AND OTHER SUPPORT SURFACES - Embodiments herein provide a flexible accessory panel with apertures from which items may be suspended. In particular, receptacles for fluids draining from a patient may be suspended from the apertures, which are retained at a level below that of the patient, maintaining a gravitational flow. Maintaining downward flow of the draining fluids limits the backflow of draining fluid to the patient and reduces the risk of infection. | 05-27-2010 |
20100120143 | INDUCTION OF APOPTOSIS AND CELL GROWTH INHIBITION BY PROTEIN 4.33 - There is disclosed an isolated cDNA sequence (SEQ ID NO:1) encoding a P4.33 polypeptide and comprising a coding region (SEQ ID NO:2) of the sequence described in SEQ ID NO:1, or a sequence having at least 90% homology with the coding region of SEQ ID NO:1. The P4.33 polypeptide functions as a specific cell-surface receptor for IGFBP-3, and undergoes nuclear translocation in combination with IGFBP-3. In particular aspects, IGFBP-3 and P4.33 (IGFBP-3R) cooperatively suppress DNA synthesis and cell growth, and induce caspase activation and apoptosis in cancer cells, indicating that P4.33 is an important mediator of IGF-independent growth inhibitory actions of IGFBP-3. The P4.33:IGFBP-3 system of the present invention can be used, inter alia, in screening and diagnostic assays, and for therapeutic methods for cancer treatment and tumor suppression. | 05-13-2010 |
20100119521 | COMPOSITIONS AND METHODS FOR TREATING CANCER BY MODULATING HER-2 AND EGF RECEPTORS - An alternative HER-2/neu product, herstatin, consists of subdomains I and II from the ectodomain of p185HER-2 and a unique 79 amino acid C-terminus encoded by intron 8. Recombinant herstatin added to cells was found to bind to and inhibit p185HER-2. The effects of ectopic expression of herstatin in combination with either p185HER-2 or with its homolog, the EGF receptor, in several cell lines was studied. Cotransfection of herstatin with HER-2 inhibited p185HER-2 levels and caused an approximate 8-fold reduction in p185 tyrosine phosphorylation. Inhibition of p185HER-2 tyrosine phosphorylation corresponded to a dramatic decline in colony formation by cells that coexpressed p185HER-2 and herstatin. Herstatin also interferred with EGF activation of the EGF receptor in cotransfected cells as demonstrated by impaired receptor tyrosine phosphorylation, reduced receptor down-regulation, and growth suppression. For both p185HER-2 and the EGF receptor, the extent of inhibition was affected by the expression levels of herstatin relative to the receptor. Herstatin is an autoinhibitor of p185HER-2 and expands its inhibitory activity to another member of the group I family of receptor tyrosine kinases, the EGF receptor. Herstatin blocked the activated Akt-mediated EGF survival signal, as well as transforming growth factor alpha (TGFα)-mediated EGF receptor activation, survival signal and proliferation signal. Purified recombinant herstatin specifically inhibited human carcinoma cells that over-express HER-2, and was effectively absorbed into the blood of intraperitoneally injected mice, where it was not proteolytically degraded and was present for between one and three hours. | 05-13-2010 |
20100016755 | METHOD AND APPARATUS FOR TINNITUS EVALUATION - Methods, articles of manufacture, and systems for evaluating tinnitus are disclosed herein. According to various embodiments, a tinnitus evaluation system may include a tinnitus evaluation module configured to perform one or more tinnitus evaluation tests. A tinnitus evaluation test may comprise generating a first single-frequency sound based at least in part on a sound of a patient's tinnitus, and generating a narrow-band sound centered at the frequency of the first single-frequency sound. Tests include a hearing threshold test, a loudness match test, a pitch match test, a bandwidth match test, a minimum masking level test, and a residual inhibition test. | 01-21-2010 |
20090281466 | DEVICE FOR REHABILITATION OF INDIVIDUALS EXPERIENCING LOSS OF SKELETAL JOINT MOTOR CONTROL - A method and device assist in the rehabilitation of patients who have suffered loss of motor control of an appendicular joint due to neurological damage. The method includes attempted contraction by a patient of a muscle that serves to move an affected joint coupled with the production of a perception by the patient that the joint is being moved more than it really is. The method results in dramatic non-transient improvements in motor control of the joint. The device provides an apparatus for performance of the method. | 11-12-2009 |
20090270316 | HER-2 BINDING ANTAGONISTS - There is disclosed a pharmaceutical composition for treating solid tumors that overexpress HER-2, comprising an agent selected from the group consisting of (a) an isolated polypeptide having from about 50 to 79 amino acids taken from the sequence of SEQ ID NO:1, wherein the polypeptide binds to the extracellular domain ECD of HER-2 at an affinity of at least 108, (b) an isolated and glycosylated polypeptide having from about 300 to 419 amino acids taken from the sequence of SEQ ID NO:2, wherein the C terminal 79 amino acids are present, and wherein at least three N-linked glycosylation sites are present, (c) a monoclonal antibody that binds to the ECD of HER-2, and (d) combinations thereof, with the proviso that the agent cannot be the monoclonal antibody alone, and pharmaceutically acceptable carrier. | 10-29-2009 |
20090253152 | NOVEL MUTANT IGFBP-3 MOLECULES THAT DO NOT BIND TO IGFs, BUT RETAIN THEIR ABILITY TO FUNCTIONALLY BIND IGFBP-3 RECEPTOR - There is disclosed novel mutant IGFBP-3 polypeptides and fragments thereof that have either no binding, or diminished binding to IGFs, yet retain their ability to bind to the human IGFBP-3 receptor (“P4.33”). The present invention provides novel mutant IGFBP-3 nucleic acid sequences, and expression systems. Additional exemplary embodiments provide for screening assays for identifying IGFBP-3 receptor antagonists or agonists, methods for modulating IGF-independent IGFBP-3 responses of cells expressing IGFBP-3 receptors, methods for inducing or potentiating apoptosis of cells expressing IGFBP-3 receptors, methods for treating solid tumors having cells expressing IGFBP-3 receptors, and compositions comprising polypeptides having either no binding, or diminished binding to IGFs, yet retain their ability to bind to the IGFBP-3 receptor. | 10-08-2009 |
20090124698 | SELECTIVE ESTROGEN RECEPTOR MODULATOR COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASE - The present disclosure concerns a new class of selective estrogen receptor modulators (SERMs). The disclosure also includes the identification of a previously unknown membrane associated estrogen receptor. Methods for making and using the disclosed SERMs are disclosed, including pharmaceutical formulations of the disclosed novel compounds in useful compositions. | 05-14-2009 |
20090105347 | THYRONAMINE DERIVATIVES AND ANALOGS AND METHODS OF USE THEREOF - Thyronamine derivatives and analogs, methods of using such compounds, and pharmaceutical compositions containing them are disclosed. Methods of preparing such compounds are also disclosed | 04-23-2009 |
20080319425 | DRUG-ELUTING GRAFT - Embodiments of the present invention provide a device for the local delivery of a substance into a natural tissue conduit in the mammalian body, having a first element capable of contacting the lumen of the conduit and a second element which overlays first element, a reservoir being formed between the first element and the second element, the interior of the reservoir being capable of fluid communication with the conduit such that a substance placed in the reservoir is delivered into the conduit. In embodiments, the first element may be fully or partially microporous or a separate intermediate microporous membrane may be provided. Also provided are methods of mixing or moving a drug within a reservoir using various mixing elements. Also provided are methods of locally delivering a substance into a natural tissue conduit in the mammalian body utilizing a device in accordance with embodiments of the present invention. | 12-25-2008 |
20080286807 | Methods and Reagents for Elimination or Reduction of False Positives in the Analysis of a Sample - Methods, apparatuses, and systems for eliminating or reducing false positives in assays are provided. More specifically, there is provided a method to absorb a false positive signal with an absorber in favor of detecting a true positive signal. Embodiments of the present invention include but are not limited to systems and methods for detecting antibodies with greater specificity than available assays and also for detecting a greater variety of antibodies. | 11-20-2008 |
20080286209 | Compositions and Methods for Treatment of Neurological Symptoms Associated with Alcohol-Withdrawal and for Consulsive Seizure - Particular aspects of the present invention provide pharmaceutical compositions comprising isoprenoid-based compounds (e.g., farnesol and/or farnesol analogues or derivatives) or dehydroisoprenoid-based compounds, and novel methods for using same in treating (e.g., suppressing): alcohol withdrawal syndrome and associated neurological symptoms (e.g., depression, tremor, anxiety, autonomic hyperactivity (e.g., sweating, increased blood pressure, tachycardia), hallucinations, alcohol withdrawal seizures, delirium tremens (DT), and memory loss); or for treating in treating convulsive seizure (e.g., epileptic seizure, etc.). Particular pharmaceutical compositions and methods comprise the use of at least one compound selected from the group consisting of: (2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-ol (all-trans farnesol); (2Z,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-ol (cis-farnesol); (E)-3,7,11-trimethyldodeca-1,6,10-trien-3-ol nerolidol); (2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-amine (farnesylamine); (E)-3-(3,7-dimethylocta-2,6-dienyloxy)phenol (geranylresorcinol); (2E,6E)-,7,11-dimethyl-3-(trifluoromethyl)dodeca-2,6,10-trien-1-ol (trifluorofarnesol); and (2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-enyl)nona-2,4,6,8-tetraen-1-ol (all-trans retinol). According to additional aspects, compounds that target and inhibit enzymes that degrade/metabolize/inactivate the disclosed compounds have utility to induce endogenous accumulation thereof to suppress/prevent, e.g., alcohol withdrawal seizures or convulsive seizures. | 11-20-2008 |
20080269463 | Tropoelastin Isoforms and Used Thereof - This disclosure provides new isoforms of tropoelastin. The disclosure further provides methods for making and using these isoforms, alone or in combination with each other or other isomers, such as in the production of biomaterials. | 10-30-2008 |
20080227761 | METHOD OF TREATING IMMUNE PATHOLOGIES WITH LOW DOSE ESTROGEN - The invention provides a method of ameliorating a Th1-mediated immune pathology in a mammal. The method is practiced by administering a low dose of estrogen to the mammal. Optionally, an immunotherapeutic agent can also be administered to the mammal. Also provided are kits containing a low dose of estrogen and an immunotherapeutic agent. | 09-18-2008 |